Lawfare in the orphan drug space
43(B)log
NOVEMBER 19, 2021
Neurelis received orphan drug designation from the FDA for its Valtoco for management of ARS in 2015. The audience was in a position to “influence” a “potential buyer” of Libervant by investing in Aquestive to help ensure that company brought Libervant to market before other competing drugs, like Valtoco.
56 
Let's personalize your content